AOD-9604 research and evidence overview

AOD-9604 has an unusual evidence profile: the animal data are specific and mechanistically coherent, the published human data say it appears safe, and the paper that would show it produces weight loss in people does not exist in the peer-reviewed literature. A PubMed search on the compound returns roughly two dozen records, dominated by anti-doping detection methodology and drug- development overviews — no randomised efficacy trial reporting weight change is among them. That absence is the single most important fact on this page.

AOD-9604 is a synthetic fragment of the C-terminus of human growth hormone, designed to keep the lipolytic activity while dropping the growth-promoting and glucose-disrupting effects of the full hormone.

In obese Zucker rats, an oral dose of 500 µg/kg daily for 19 days cut body weight gain by more than half (15.8 ± 0.6 g versus 35.6 ± 0.8 g in controls), with increased lipolytic activity in adipose tissue and — critically — no impairment of insulin sensitivity on euglycaemic clamp, unlike chronic treatment with intact hGH (Ng et al., Hormone Research 2000, PMID 11146367).

A follow-up in Endocrinology traced the mechanism. Fourteen days of intraperitoneal AOD-9604 reduced body weight and fat in obese mice and raised the depressed expression of β3-adrenergic receptor RNA toward lean-mouse levels. In β3-AR knockout mice, chronic treatment failed to produce weight loss — so the lipolytic effect depends on that pathway, even though the peptide does not act directly on the receptor (Heffernan et al., 2001, PMID 11713213).

The main human publication is a pooled safety analysis from the developer, covering six randomised, double-blind, placebo-controlled trials (Stier, Vos & Kenley, Journal of Endocrinology and Metabolism 2013, DOI 10.4021/jem157w). Its conclusions: a safety and tolerability profile described as indistinguishable from placebo, no negative effect on carbohydrate metabolism, no immunogenic antibodies detected, and no withdrawals or serious adverse events across the studies.

Read what that paper is and is not. It is a safety summary written by parties with a commercial interest, published in a journal not indexed in PubMed. It reports no weight-loss outcome, no effect size, and no primary endpoint result. "Safe in trials" is a genuinely useful finding; it is not evidence that the compound works.

AOD-9604 went through clinical development as an anti-obesity candidate and was not approved. It has no FDA-approved indication. A 2026 narrative review in Sports Medicine covering the direct-to-patient peptide market places AOD-9604 alongside BPC-157, CJC-1295 and TB-500 in the category of compounds with favourable animal data but scarce rigorous human safety and efficacy evidence (Mendias & Awan, PMID 41966639). When a peptide's marketing cites "clinical trials," the reasonable question is which endpoint those trials reported — for AOD-9604, the published answer is safety.

A smaller line of work has looked at joints rather than fat. In a collagenase-induced knee osteoarthritis model in 32 rabbits, weekly ultrasound-guided intra-articular injections of 0.25 mg AOD-9604, alone or with hyaluronic acid, improved gross morphological and histopathological cartilage scores versus saline, with the combination outperforming either agent alone and shortening the lameness period (Kwon & Park, Annals of Clinical and Laboratory Science 2015, PMID 26275694). This is a single small animal study in one injury model and has not been followed by human work.

The remainder of the AOD-9604 literature is anti-doping analytical chemistry — methods for detecting the peptide in urine and blood, and confirmation that it does not interfere with WADA's hGH isoform immunoassay. That body of work tells you the compound is circulating in the gray market, not that it does what sellers claim.